Navigation Links
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
Date:7/16/2008

Raptor to Support Phase 2a Clinical Trial at UCSD

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the execution of a collaboration agreement (the "Agreement") with the University of California, San Diego ("UCSD") to include a Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate ("Cysteamine") in adolescents diagnosed with Non-Alcoholic Steatohepatitis ("NASH"). NASH is a progressive form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, and ranks as one of the leading causes of cirrhosis of the liver in the U.S.

Under the terms of the Agreement, clinical researchers from UCSD will perform the Phase 2a study at the University's General Clinical Research Center, and Raptor will provide funding and clinical supply of Cysteamine. In March 2008, Raptor acquired an exclusive, worldwide license to certain intellectual property and development rights from UCSD surrounding the use of Cysteamine as a potential treatment for NASH.

A rapid-release form of Cysteamine is currently approved for sale by the U.S. Food and Drug Administration ("FDA") for the treatment of nephropathic cystinosis, a rare, genetic lysosomal storage disease. Raptor is currently developing DR Cysteamine, a proprietary, delayed-release formulation of Cysteamine, designed to improve bioavailability and potentially reduce side effects associated with the presently marketed form.

Ted Daley, President of Raptor's clinical division stated, "We look forward to working with UCSD, one of the leading research universities in the nation, under this collaboration agreement. The University's clinical researchers have specific expertise in treating NASH patients, and have also worked extensively with Cysteamine. We are fortunate to work with this team to investigate our drug candidate
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Raptor Pharmaceuticals Provides Update of Product Programs
3. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
6. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
7. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
10. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
(Date:9/30/2014)... , Sept. 30, 2014   Decision Resources ... claims data, anemic chronic kidney disease non-dialysis (CKD-ND) ... agent (ESA) medication. In addition, one-year persistency is ... Other key findings from the report ... Analysis of Erythropoiesis Stimulating Agents in Late Stage ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014  Arena ... (PLM) applications, today announced its Fall 2014 release, ... Scribe and Arena DataExtract – ... The newly available products are focused specifically on ... and the aggregation of a complete history of ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 4
(Date:9/30/2014)... Alan Mozes Health Day Reporter ... Colon cancer patients who are overweight or obese when ... developing a second weight-related cancer, new research suggests. , ... colon cancer recurrence, only the potential for developing other ... colorectal cancer survivors who reported being overweight or obese ...
(Date:9/30/2014)... Next to lung cancer, breast cancer is the leading ... American Cancer Society. That,s why so many medical professionals ... are imperfect at best: only a minority of suspicious ... results in lots of needless worry for women and ... of additional tests, including ultrasounds and biopsies. , ...
(Date:9/30/2014)... CO September 30, 2014 Keystone Symposia will ... the first in its 2014-15 Global Health Series ... the Sheraton Seattle Hotel immediately following the conclusion ... The four-day conference is part of the Keystone Symposia ... Gates Foundation, which has also funded travel awards for ...
(Date:9/30/2014)... A new study of 58 ... impact of stress on metabolism after eating a high-fat meal ... a fast food restaurant, about 930 calories and 60 grams ... minutes every hour for 7 hours, conducting the study twice ... had experienced a stressful event in their lives during the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... in motor vehicle crashes is closely correlated to the severity ... at the Medical College of Wisconsin in Milwaukee. ... rupture, resulting in bleeding onto the surface of the retina. ... M.D., professors of ophthalmology at the Medical College, is published ...
... for Devastating ... Neurological Disease -, HAILEY, Idaho, June 23 Charles ... on June 17, 2008, for,his support to find a cure for the ... or Parkinson,s disease. Chuck has had PSP for several years,and, despite his ...
... Pacific Corporation, one of,this country,s best kept secrets in ... as part of its current offering to existing and ... review all,financial information up to the second from their ... "We are excited to be able to offer this ...
... Findley Davies, Inc., a human,resources consulting firm, ... Association of Business Communicators (IABC) Cleveland Vision,Awards. For ... HCR,ManorCare, Findley Davies Communication Solutions practice received an,Award ... Davies Communication Solutions practice also received an Award ...
... Insurance,Company ("The Standard"), a subsidiary of StanCorp Financial ... insurance products for employers with as,few as 10 ... line, The,Standard now provides employers with the opportunity ... term disability, life, dental,and vision insurance from a ...
... patients who need little, if any, immune suppression , , ... called HLA-G dimer plays a powerful role in preventing ... Medical College of Georgia researchers say. , They ... mice and are currently studying whether this molecule is ...
Cached Medicine News:Health News:Severe retinal hemorrhaging is linked to severe motor vehicle crashes 2Health News:Advertising Hall of Famer Charles D. Peebler Receives Honor for Work Supporting Cure for Progressive Supernuclear Palsy 2Health News:Oregon Based First Pacific Corporation Launches New E-Tools Program for Dentists 2Health News:Findley Davies Receives IABC Vision Awards 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 3Health News:Immune Molecule Key to Preventing Organ Rejection 2
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Medicine Products: